Search Result
Results for "
Antithrombotic Agent
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-U00383
-
-
-
- HY-101054
-
-
-
- HY-117824
-
|
|
Others
|
Others
|
|
L-703014 is a fibrinogen receptor antagonist, with the IC50 of 94 nM, that acts as a novel parenteral and potential oral antithrombotic agent .
|
-
-
- HY-19052
-
-
-
- HY-105919
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
|
-
-
- HY-105559
-
|
Quinotoxine
|
Others
|
Cardiovascular Disease
|
|
Viquidil (Quinotoxine), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil shows antithrombotic activity .
|
-
-
- HY-105559A
-
|
Quinotoxine hydrochloride
|
Others
|
Cardiovascular Disease
|
|
Viquidil hydrochloride (Quinotoxine hydrochloride), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil hydrochloride shows antithrombotic activity .
|
-
-
- HY-P5889
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
Thrombin receptor peptide ligand is a thrombin receptor antagonist peptide that can be used as an antithrombotic agent .
|
-
-
- HY-110043
-
|
|
Others
|
Cardiovascular Disease
|
|
(±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors .
|
-
-
- HY-B1271
-
|
G-28315
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects .
|
-
-
- HY-112624P
-
|
Dextran 500; Dextran D500; Dextran T500(MW 440000-560000)
|
Biochemical Assay Reagents
|
Others
|
|
Dextran T500 MW 500,000 (Dextran 500; Dextran D500; Dextran T500 MW 440000-560000) is a polymer of anhydroglucose with the average molecular weight of 500,000. Dextran T500 MW 500,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .
|
-
-
- HY-112624D
-
|
Dextran 60; Dextran D60; Dextran T60(MW 54000-66000)
|
Biochemical Assay Reagents
|
Others
|
|
Dextran T60 MW 60,000 (Dextran 60; Dextran D60; Dextran T60 MW 54000-66000) is a polymer of anhydroglucose with the average molecular weight of 60,000. Dextran T60 MW 60,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .
|
-
-
- HY-112624Q
-
|
Dextran 800; Dextran D800; Dextran T800(MW 750000-850000)
|
Biochemical Assay Reagents
|
Others
|
|
Dextran T800 MW 800,000 (Dextran 800; Dextran D800; Dextran T800 MW 750000-850000) is a polymer of anhydroglucose with the average molecular weight of 800,000. Dextran T800 MW 800,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .
|
-
-
- HY-129496
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca 2+ inward flow .
|
-
-
- HY-B1271R
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Sulfinpyrazone (Standard) is the analytical standard of Sulfinpyrazone. This product is intended for research and analytical applications. Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects .
|
-
-
- HY-106784
-
|
|
Fungal
Apoptosis
|
Infection
Cancer
|
|
Ajoene, a garlic-derived compound, is an antithrombotic and antifungal agent. Ajoene inhibits proliferation and induces apoptosis of human leukaemia CD34-negative cells including HL-60, U937, HEL and OCIM-I. Anticancer activities .
|
-
-
- HY-111755
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
|
-
-
- HY-17459
-
|
(S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate
|
Cytochrome P450
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
|
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
|
-
-
- HY-115911
-
|
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent .
|
-
-
- HY-115912
-
|
|
Glycoprotein VI
|
Cardiovascular Disease
|
|
GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .
|
-
-
- HY-137227
-
|
15(R)-Pinanethromboxane A2
|
Others
|
Cardiovascular Disease
|
|
15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .
|
-
-
- HY-17459S
-
|
(S)-(+)-Clopidogrel bisulfate-d3; (S)-(+)-Clopidogrel-d3 hydrogen sulfate
|
P2Y Receptor
Cytochrome P450
|
|
|
Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
|
-
-
- HY-17459R
-
|
(S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)
|
Cytochrome P450
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
|
Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
|
-
-
- HY-129611
-
|
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .
|
-
-
- HY-10274
-
|
BIBR 1048
|
Thrombin
|
Cardiovascular Disease
|
|
Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
|
-
-
- HY-10274A
-
|
BIBR 1048MS; Dabigatran etexilate methanesulfonate
|
Thrombin
|
Cardiovascular Disease
|
|
Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
|
-
-
- HY-10274AR
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
Dabigatran etexilate (mesylate) (Standard) is the analytical standard of Dabigatran etexilate (mesylate). This product is intended for research and analytical applications. Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
|
-
-
- HY-P4721
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a KD < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .
|
-
-
- HY-10264S
-
|
DU-176-d6
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
|
Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-112624P
-
|
Dextran 500; Dextran D500; Dextran T500(MW 440000-560000)
|
Thickeners
|
|
Dextran T500 MW 500,000 (Dextran 500; Dextran D500; Dextran T500 MW 440000-560000) is a polymer of anhydroglucose with the average molecular weight of 500,000. Dextran T500 MW 500,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .
|
-
- HY-112624D
-
|
Dextran 60; Dextran D60; Dextran T60(MW 54000-66000)
|
Thickeners
|
|
Dextran T60 MW 60,000 (Dextran 60; Dextran D60; Dextran T60 MW 54000-66000) is a polymer of anhydroglucose with the average molecular weight of 60,000. Dextran T60 MW 60,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .
|
-
- HY-112624Q
-
|
Dextran 800; Dextran D800; Dextran T800(MW 750000-850000)
|
Thickeners
|
|
Dextran T800 MW 800,000 (Dextran 800; Dextran D800; Dextran T800 MW 750000-850000) is a polymer of anhydroglucose with the average molecular weight of 800,000. Dextran T800 MW 800,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P5889
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
Thrombin receptor peptide ligand is a thrombin receptor antagonist peptide that can be used as an antithrombotic agent .
|
-
- HY-P4721
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a KD < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-10264S
-
|
|
|
Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
|
-
-
- HY-17459S
-
|
|
|
Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
